WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 2740

Legislative bill overview

HB 2740 establishes a governance board at the University of Missouri tasked with overseeing and reporting on research initiatives related to rare pediatric diseases. The bill creates an institutional framework to coordinate rare disease research efforts and presumably track progress through regular reporting mechanisms. This represents a formal commitment to prioritizing pediatric rare disease research within Missouri's flagship university system.

Why is this important

Rare pediatric diseases affect relatively small populations, making them less commercially attractive for pharmaceutical development and research funding. By establishing a dedicated governance structure, Missouri aims to fill gaps in research coordination and visibility for conditions that might otherwise lack institutional attention. Enhanced reporting and coordination could accelerate discoveries and improve access to clinical trials for affected families.

Potential points of contention

  • Funding requirements: The bill's fiscal impact remains unclear—whether it requires new appropriations or redirects existing university resources to staff and operate the governance board
  • Scope definition: "Rare pediatric disease" lacks a precise legal definition in the summary, potentially creating ambiguity about which conditions and research projects fall under the board's purview
  • Administrative burden: Creating additional governance layers at universities can increase bureaucratic overhead without guaranteeing research acceleration or improved outcomes

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.